# US 2017/0281803 A1 · Renal imaging agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281803 A1
- Document ID: US20170281803A1
- Status: Published application
- Kind: A1
- Application number: 15/508,325
- Filed: 2015-09-07
- Published: 2017-10-05
- Earliest claimed: 2014-09-25
- Assignees: Nihon Medi-Physics Co., Ltd.
- Applicants: Nihon Medi-Physics Co., Ltd.
- Inventors: Norihito NAKATA
- Web page: https://patentgrep.com/patent/US20170281803A1

## CPC

- A61K 51/0453: {having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}
- A61K 51/00: Preparations containing radioactive substances for use in therapy or testing in vivo
- C07D 233/91: Nitro radicals
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention provides a renal imaging agent comprising a nitroimidazole-type compound or a salt thereof. The renal imaging agent according to the present invention can be used in positron emission tomography.

## Claims

### Claim 1

A renal imaging agent comprising a nitroimidazole-based compound represented by the general formula (1) shown below, or a salt thereof.
wherein R1 is hydrogen or a hydroxymethyl group, and A is any one of the groups (I) to (IV) shown below:
wherein R2 is hydrogen or a hydroxy group, R3 is hydrogen or a hydroxymethyl group, R4 is a hydroxy group or a hydroxymethyl group, k is 0 or 1, m is 0 or 1, n is 0, 1 or 2, and X is radioactive fluorine;
wherein n is 0, 1 or 2, p is 1 or 2, q is 0, 1 or 2, and X is a radioactive fluorine;
wherein n is 0, 1 or 2, and X is a radioactive fluorine; and
wherein n is 0, 1 or 2, and X is a radioactive fluorine.

### Claim 2 (depends on 1)

The renal imaging agent according to claim 1, wherein the nitroimidazole-based compound is
2-[18F]fluoromethyl-2-((2-nitro-1H-imidazol-1-yl)methyl)-1,3-propanediol;
2-[18F]fluoromethyl-2-((4-hydroxymethyl-2-nitro-1H-imidazol-1-yl)methyl)-1,3-propanediol;
2-[18F]fluoromethyl-2-(2-(2-nitro-1H-imidazol-1-yl)ethyl)-1,3-propanediol;
1-[18F]fluoro-3-(2-nitro-1H-imidazol-1-yl)-2-propanol;
1-[18F]fluoro-4-(2-nitro-1H-imidazol-1-yl)-2,3-butanediol;
3-[18F]fluoro-2-((2-nitro-1H-imidazol-1-yl)methoxy)-1-propanol;
N-(2-[18F]fluoroethyl)-2-nitro-1H-imidazole-1-acetamide;
2-nitro-N-(2,2,3,3,3-[18F]pentafluoropropyl)-1H-imidazole-1-acetamide;
(3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-propanol; or
1-(5-deoxy-5-[18F]fluoro-α-D-arabinofuranosyl)-2-nitro-1H-imidazole.

### Claim 3 (depends on 1)

The renal imaging agent according to claim 1, wherein the nitroimidazole-based compound is a compound having a log P at 25° C. lower than a log P of 1-[18F]fluoro-3-(2-nitro-1H-imidazol-1-yl)-2-propanol.

### Claim 4 (depends on 1)

The renal imaging agent according to claim 1, which is used for positron emission tomography.
